Bayer aspirin MI petition
This article was originally published in The Tan Sheet
Executive Summary
FDA should evaluate collected study data on aspirin for primary prevention of myocardial infarction "expeditiously," Bayer urges in Feb. 22 comments supporting the firm's petition to amend professional labeling to include the indication. The firm submitted data and protocols from five major prevention trials through Colin Baigent, MD, of Oxford's Clinical Trials Study Unit. Baigent previously presented a meta-analysis of the trials at a December 2003 meeting of the Cardiovascular & Renal Drugs Advisory Committee, convened to consider Bayer's petition (1"The Tan Sheet" Dec. 15, 2003, p. 4). The panel voted 11-3 against the new labeling, but the agency requested more information at an April 2004 feedback meeting...
You may also be interested in...
Aspirin For MI Primary Prevention Indication Needs More Study, Panel Says
A long-term randomized prospective trial of at least 15,000 patients would be needed to adequately support professional aspirin labeling on primary prevention of myocardial infarction, according to members of FDA's Cardiovascular & Renal Drugs Advisory committee
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.